A federal appeals court blocked the mailing of mifepristone, restricting access to one of the most common abortion methods in the United States. The ruling limits how the drug can be distributed, potentially affecting thousands of patients who rely on mail delivery for medication abortion. Mifepristone is used in combination with misoprostol to end pregnancies up to 10 weeks. The restriction comes as abortion access remains deeply contested across the country following the Supreme Court's 2022 decision to overturn Roe v. Wade, which eliminated the federal right to abortion and returned regulation to individual states. Some states have since banned or severely restricted abortion, while others have protected access. The mailing restriction complicates the landscape further, as it prevents patients in some states from obtaining the drug by mail, a method that has grown in use over the past two years. The decision sets up a likely legal battle over whether the restriction will stand, with abortion-rights advocates expected to challenge the ruling. The case reflects ongoing judicial intervention in abortion policy at the federal level, even as states remain the primary regulators of abortion access.